Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.

Dultz G, Seelhof M, Herrmann E, Welker MW, Friedrich-Rust M, Teuber G, Kronenberger B, von Wagner M, Vermehren J, Sarrazin C, Zeuzem S, Hofmann WP.

PLoS One. 2013 Aug 1;8(8):e71262. doi: 10.1371/journal.pone.0071262. Print 2013.

2.

Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.

Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.

Gastroenterology. 2014 Feb;146(2):442-52.e1. doi: 10.1053/j.gastro.2013.10.012. Epub 2013 Oct 12.

PMID:
24126097
3.

Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.

Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas.

Clin Infect Dis. 2013 Jun;56(11):1646-53. doi: 10.1093/cid/cit103. Epub 2013 Feb 19.

4.

Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.

Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Zangneh HF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ.

J Hepatol. 2014 Sep;61(3):482-91. doi: 10.1016/j.jhep.2014.04.021. Epub 2014 Apr 26.

PMID:
24780302
5.

Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.

Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Borzio M, Redaelli A, Chiesa A, Silini EM, Almasio PL, Maisonneuve P.

Am J Gastroenterol. 2009 May;104(5):1147-58. doi: 10.1038/ajg.2009.31. Epub 2009 Apr 7.

PMID:
19352340
6.

Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.

Hofer H, Gurguta C, Bergholz U, Steindl-Munda P, Ferenci P.

Wien Klin Wochenschr. 2006 Oct;118(19-20):595-600.

PMID:
17136334
7.

Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.

Labarga P, Fernández-Montero JV, de Mendoza C, Barreiro P, Soriano V.

Antivir Ther. 2015;20(1):65-72. doi: 10.3851/IMP2827. Epub 2014 Aug 8.

PMID:
25105286
8.

Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C.

Martínez-Macías RF, Cordero-Pérez P, Juárez-Rodríguez OA, Chen-López CY, Martínez-Carrillo FM, Alarcón-Galván G, Mercado-Hernández R, Muñoz-Espinosa LE.

Ann Hepatol. 2015 Jan-Feb;14(1):36-45.

9.

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.

Kim KH, Jang BK, Chung WJ, Hwang JS, Kweon YO, Tak WY, Lee HJ, Lee CH, Suh JI.

Korean J Hepatol. 2011 Sep;17(3):220-5. doi: 10.3350/kjhep.2011.17.3.220.

10.

Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.

Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN.

Dig Dis Sci. 2009 Dec;54(12):2699-705. doi: 10.1007/s10620-008-0683-2.

PMID:
19148751
11.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf.

PMID:
23395996
12.

Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.

Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, Abraldes JG, Bosch J, Sanchez-Tapias JM, Forns X, García-Pagán JC.

Clin Gastroenterol Hepatol. 2015 Oct;13(10):1846-1853.e1. doi: 10.1016/j.cgh.2015.04.013. Epub 2015 Apr 23.

PMID:
25912838
13.

The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C.

Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ.

Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1192-9. doi: 10.1097/MEG.0b013e32834c5b32.

PMID:
21971375
14.

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X.

Gastroenterology. 2007 May;132(5):1746-56. Epub 2007 Mar 24.

PMID:
17484872
15.

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M.

Ann Saudi Med. 2009 Jan-Feb;29(1):4-14.

16.

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50. doi: 10.1097/MEG.0b013e3283513e69.

PMID:
22337287
17.

Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.

Di Martino V, Crouzet J, Hillon P, Thévenot T, Minello A, Monnet E.

J Viral Hepat. 2011 Jul;18(7):493-505. doi: 10.1111/j.1365-2893.2011.01476.x. Epub 2011 May 27.

PMID:
21692956
18.

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.

Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group.

J Infect Dis. 2012 Sep 15;206(6):961-8. Epub 2012 Jul 17.

19.

Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.

Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimägi L, Tefanova V.

Cent Eur J Public Health. 2012 Jun;20(2):150-5.

20.

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC3 Study Group.

Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17. Erratum in: Gastroenterology. 2013 Oct;145(4):910.

PMID:
21419770
Items per page

Supplemental Content

Write to the Help Desk